Faculty

Stefano B Rivella, PhD

Professor of Pediatrics (Hematology)

Department: Pediatrics

Graduate Group Affiliations

Cell and Molecular Biology

Contact information

Children’s Hospital of Philadelphia
3615 Civic Center Blvd.
Abramson Research Center, Room 316B
Philadelphia, PA 19104

https://www.med.upenn.edu/apps/faculty/index.php/g275/p8859218
https://www.linkedin.com/in/stefano-rivella-9b5a489a
Philadelphia, PA 19104

Office: 215-590-6840
Fax: 267-426-5476

Email:
rivellas@chop.edu

Publications

Search PubMed for articles

Education:
BSc
University of Pavia, 1990.
PhD
University of Pavia, 1999.

Links
Search PubMed for articles
European Medicines Agency (EMA), Scientific Committee members and experts
La Talassemia: dai Laboratori di Ricerca alla Società (parte quarta)
Hormone's Crucial Role in 2 Anemic Blood Disorders Revealed
Blood Disorders Mechanics Deconstructed
Reducing TMPRSS6 ameliorates hemochromatosis and beta-thalassemia in mice
Dr. Rivella and team find new gene therapy approach
Development minihepcidin compound
Medgenics Announces Beta Thalassemia Research Program
Perspective: Speed Networking for Scientists
Researchers Discover Hormone that Controls Supply of Iron in Red Blood Cell Production

Permanent link

> Perelman School of Medicine > Faculty > Details

Selected Publications

Pham V, Tricoli L, Hong X, Wongkittichote P, Castruccio Castracani C, Guerra A, Schlotawa L, Adang LA, Kuhs A, Cassidy MM, Kane O, Tsai E, Presa M, Lutz C, Rivella SB, Ahrens-Nicklas RC.: Hematopoietic stem cell gene therapy improves outcomes in a clinically relevant mouse model of multiple sulfatase deficiency. Mol Ther Aug 2024.

Chappell ME, Breda L, Tricoli L, Guerra A, Jarocha DJ, Castruccio Castracani C, Papp TE, Tanaka N, Hamilton N, Triebwasser MP, Ghiaccio V, Fedorky M, Gollomp K, Bochenek V, Roche AM, Everett JK, Cook EJ, Bushman FD, Teawtrakul N, Glentis S, Kattamis A Prof, Mui BL, Tam YK, Weissman D, Abdulmalik O, Parhiz H, Rivella S.: Use of HSC Targeted LNP to Generate a Mouse Model of Lethal α-Thalassemia and Treatment via Lentiviral Gene Therapy. Blood Jul 2024.

Rivella S.: Optimizing lentiviral genomic integrations to cure beta-thalassemia: The least required for success? Mol Ther Methods Clin Dev 32: 101222, Mar 2024.

Tricoli L, Sase S, Hacker J, Pham V, Smith S, Chappell M, Breda L, Hurwitz S, Tanaka N, Castracani CC, Guerra A, Hou Z, Schlotawa L, Radhakrishnan K, Kurre P, Ahrens-Nicklas R, Adang L, Vanderver A, Rivella S.: Effective Gene Therapy for Metachromatic Leukodystrophy Achieved with Minimal Lentiviral Genomic Integrations. bioRxiv Mar 2024.

Guerra A, Hamilton N, Rivera A, Demsko P, Guo S, Rivella S.: Combination of a TGF-β ligand trap (RAP-GRL) and TMPRSS6-ASO is superior for correcting β-thalassemia. Am J Hematol 2024.

Castro OL, De Franceschi L, Ganz T, Kanter J, Kato GJ, Pasricha SR, Rivella S, Wood JC.: Iron restriction in sickle cell disease: When less is more. Am J Hematol 2024.

Liang R, Lin M, Menon V, Qiu J, Menon A, Breda L, Arif T, Rivella S, Ghaffari S.: Elevated CDKN1A (P21) mediates β-thalassemia erythroid apoptosis, but its loss does not improve β-thalassemic erythropoiesis. Blood Adv 7: 6873-6885, Nov 2023.

Ginzburg Y, An X, Rivella S, Goldfarb A.: Normal and dysregulated crosstalk between iron metabolism and erythropoiesis. Elife 12: e90189, Aug 2023.

Breda L, Papp TE, Triebwasser MP, Yadegari A, Fedorky MT, Tanaka N, Abdulmalik O, Pavani G, Wang Y, Grupp SA, Chou ST, Ni H, Mui BL, Tam YK, Weissman D, Rivella S, Parhiz H.: In vivo hematopoietic stem cell modification by mRNA delivery. Science 381: 436-443, Jul 2023.

Guerra A, Parhiz H, Rivella S.: Novel potential therapeutics to modify iron metabolism and red cell synthesis in diseases associated with defective erythropoiesis. Haematologica Jun 2023.